Joseph Horrigan
Directeur Technique/Scientifique/R&D chez AMO Pharma Ltd.
Profil
Joseph Horrigan is currently an Associate Professor at The University of North Carolina at Charlotte and the Chief Medical Officer at AMO Pharma Ltd.
He previously worked as the VP-Clinical Development & Medical Affairs at Neuren Pharmaceuticals Ltd.
He earned a doctorate degree from the University of Rochester.
Postes actifs de Joseph Horrigan
| Sociétés | Poste | Début |
|---|---|---|
| The University of North Carolina at Charlotte | Corporate Officer/Principal | - |
AMO Pharma Ltd.
 AMO Pharma Ltd. BiotechnologyHealth Technology AMO Pharma Ltd. engages in the development of biopharmaceutical products. It develops and identifies and advance therapies for people affected by serious and debilitating diseases, particularly rare or orphan diseases. The company was founded by Michael F. Snape on February 10, 2015 and is headquartered in Leeds, United Kingdom. | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Joseph Horrigan
| Sociétés | Poste | Fin |
|---|---|---|
| NEUREN PHARMACEUTICALS LIMITED | Directeur Technique/Scientifique/R&D | - |
Formation de Joseph Horrigan
| Rochester Christian University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NEUREN PHARMACEUTICALS LIMITED | Health Technology |
| Entreprise privées | 1 |
|---|---|
AMO Pharma Ltd.
AMO Pharma Ltd. BiotechnologyHealth Technology AMO Pharma Ltd. engages in the development of biopharmaceutical products. It develops and identifies and advance therapies for people affected by serious and debilitating diseases, particularly rare or orphan diseases. The company was founded by Michael F. Snape on February 10, 2015 and is headquartered in Leeds, United Kingdom. | Health Technology |
